Brief: Newly FDA-Approved Revtorpyk™ (Gedatolisib) Included In The National Comprehensive Cancer Network® (Nccn®) Clinical Practice Guidelines For Hr+/Her2- Locally Advanced Or Metastatic Breast Cancer
30/07/2026 13:40
BRIEF-Newly FDA-Approved Revtorpyk™ (Gedatolisib) Included In The National Comprehensive Cancer Network® (Nccn®) Clinical Practice Guidelines For Hr+/Her2- Locally Advanced Or Metastatic Breast Cancer July 30 (Reuters) - Celcuity Inc CELC.O:
NEWLY FDA-APPROVED REVTORPYK™ (GEDATOLISIB) INCLUDED IN THE NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CLINICAL PRACTICE GUIDELINES FOR HR+/HER2- LOCALLY ADVANCED OR METASTATIC BREAST CANCER
CELCUITY - FDA APPROVES REVTORPYK FOR HR+/HER2- ADVANCED BREAST CANCER WITHOUT PIK3CA MUTATION ON JULY 14, 2026
CELCUITY - REVTORPYK EXPECTED TO BE COMMERCIALLY AVAILABLE IN U.S. IN LATE Q3 2026
Source text: ID:nGNX4NXtDJ
Further company coverage: CELC.O
((Reuters.Briefs@thomsonreuters.com;))